Anthem Biosciences share news, announcements and annual reports
NSE: ANTHEMBSE: 544449Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹837.15.
28 Oct: open ₹834.00, high ₹836.55, low ₹827.05
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46,894 Cr226th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 81.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 15.41
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.24%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 18.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 65,49148.3% delivered
Anthem Biosciences has 64 announcements on record, routine notices left out; 1 in the 30 days to 29 Oct 2026, the latest on 28 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Anthem Biosciences quarterly results
The board meets on 3 Nov 2026 to consider financial results
Notice filed 28 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Anthem Biosciences annual reports, presentations and earnings calls
The company's own documents, latest first.Anthem Biosciences financials, year by year
Annual reports1
- Annual report, year to Mar 202630 Jun 2026
Investor presentations6
- Investor Presentation21 Jul 2026
- Investor Presentation21 Jul 2026
- Investor Presentation19 May 2026
- Investor Presentation5 Feb 2026
- Investor Presentation8 Nov 2025
1 earlier presentation
- Investor Presentation13 Aug 2025
Earnings calls10
- Transcript27 Jul 2026
- Link of Recording22 Jul 2026
- Transcript22 May 2026
- Link of Recording20 May 2026
- Transcript9 Feb 2026
5 earlier call documents
- Submission of Audio recordings of Earnings Call for the quarter and nine months ended December 31, 20255 Feb 2026
- Transcript12 Nov 2025
- Link of Recording10 Nov 2025
- Transcript18 Aug 2025
- Link of Recording14 Aug 2025
Anthem Biosciences share news and announcements
Newest first. Page 1 of 2.
Oct 2026
28 Oct · Board meeting
Sep 2026
8 Sep · Updates
Jul 2026
22 Jul · Meeting
21 Jul · Results
15 Jul · Analysts
14 Jul · Board meeting
3 Jul · Rating
Jun 2026
30 Jun · Updates
17 Jun · Legal
Exchange has sought clarification from Anthem Biosciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.5 Jun · Analysts
May 2026
22 May · Analysts
12 May · Analysts
Apr 2026
22 Apr · Management
Mar 2026
Feb 2026
Jan 2026
27 Jan · Analysts
27 Jan · Analysts
27 Jan · Board meeting
Dec 2025
15 Dec · Analysts
Nov 2025
Oct 2025
23 Oct · Analysts
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 22 Jul 2026Resultsdown 1.60%−0.7 pts vs Nifty 500market median −0.7% · five sessions −1.0% (0.0 pts vs Nifty 500) · volume 6.6× usual · delivery +6.0 pts against usual · The announcement
- 3 Jul 2026Credit ratingdown 0.19%−0.3 pts vs Nifty 500market median 0.0% · five sessions −2.6% (−1.8 pts vs Nifty 500) · volume 0.6× usual · delivery −1.5 pts against usual · The announcement
- 16 Mar 2026Board or managers changedup 0.68%+0.2 pts vs Nifty 500market median 0.0% · five sessions +0.7% (+1.0 pts vs Nifty 500) · volume 0.7× usual · delivery +0.1 pts against usual · The announcement
- 5 Feb 2026Resultsup 4.91%+5.4 pts vs Nifty 500market median −0.7% · five sessions +14.3% (+13.3 pts vs Nifty 500) · volume 4.1× usual · delivery −13.0 pts against usual · The announcement
- 14 Aug 2025Resultsup 9.27%+9.4 pts vs Nifty 500market median −0.7% · five sessions +12.1% (+10.2 pts vs Nifty 500) · delivery −21.4 pts against usual · The announcement
Anthem Biosciences results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Earnings per share | Year to date to Mar 2026 | Consolidated | 21.10 | 10.55 | −50.0% | 24 Jun 2026 | 21 Sep 2026 |
| Earnings per share | Quarter to Mar 2026 | Consolidated | 6.76 | 3.38 | −50.0% | 24 Jun 2026 | 21 Sep 2026 |
| Earnings per share | Year to Mar 2026 | Consolidated | 21.10 | 10.55 | −50.0% | 24 Jun 2026 | 21 Sep 2026 |
| Diluted earnings per share | Year to date to Mar 2026 | Consolidated | 20.86 | 10.43 | −50.0% | 24 Jun 2026 | 21 Sep 2026 |
| Diluted earnings per share | Quarter to Mar 2026 | Consolidated | 6.68 | 3.34 | −50.0% | 24 Jun 2026 | 21 Sep 2026 |
| Diluted earnings per share | Year to Mar 2026 | Consolidated | 20.86 | 10.43 | −50.0% | 24 Jun 2026 | 21 Sep 2026 |